Maddison Knight
Overview
Explore the profile of Maddison Knight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferriero R, Bruno G, Padula A, Pisano S, Boffa I, Gargaro M, et al.
Nat Commun
. 2025 Mar;
16(1):2118.
PMID: 40064861
Liver fibrosis, characterized by scar tissue accumulation due to liver injury, poses significant barriers to liver-targeted gene therapy. Current clinical trials exclude patients with fibrosis, as intact liver architecture is...
2.
Westhaus A, Barba-Sarasua E, Chen Y, Hsu K, Scott S, Knight M, et al.
Mol Ther
. 2024 Dec;
PMID: 39673125
Chimeric antigen receptor (CAR) T cell (CAR-T) therapies present options for patients diagnosed with certain leukemias. Recent advances of the technology included a method to integrate the CAR into the...
3.
Cabanes-Creus M, Liao S, Navarro R, Knight M, Nazareth D, Lau N, et al.
Nat Commun
. 2024 Mar;
15(1):1876.
PMID: 38485924
Developing clinically predictive model systems for evaluating gene transfer and gene editing technologies has become increasingly important in the era of personalized medicine. Liver-directed gene therapies present a unique challenge...
4.
Drouyer M, Merjane J, Nazareth D, Knight M, Scott S, Liao S, et al.
Mol Ther
. 2024 Feb;
32(3):818-836.
PMID: 38297833
Directed evolution of natural AAV9 using peptide display libraries have been widely used in the search for an optimal recombinant AAV (rAAV) for transgene delivery across the blood-brain barrier (BBB)...
5.
Westhaus A, Eamegdool S, Fernando M, Fuller-Carter P, Brunet A, Miller A, et al.
Sci Rep
. 2023 Dec;
13(1):21946.
PMID: 38081924
Adeno-associated viral (AAV) vector-mediated retinal gene therapy is an active field of both pre-clinical as well as clinical research. As with other gene therapy clinical targets, novel bioengineered AAV variants...
6.
Kok C, Tsurusaki S, Cabanes-Creus M, Igoor S, Rao R, Skelton R, et al.
Mol Ther Methods Clin Dev
. 2023 Sep;
30:459-473.
PMID: 37674904
Recombinant adeno-associated viruses (rAAVs) have emerged as one of the most promising gene therapy vectors that have been successfully used in pre-clinical models of heart disease. However, this has not...
7.
Cabanes-Creus M, Navarro R, Liao S, Scott S, Carlessi R, Roca-Pinilla R, et al.
Mol Ther Methods Clin Dev
. 2023 Jan;
28:220-237.
PMID: 36700121
Recent clinical successes have intensified interest in using adeno-associated virus (AAV) vectors for therapeutic gene delivery. The liver is a key clinical target, given its critical physiological functions and involvement...
8.
Westhaus A, Cabanes-Creus M, Rybicki A, Baltazar G, Navarro R, Zhu E, et al.
Hum Gene Ther
. 2020 Feb;
31(9-10):575-589.
PMID: 32000541
Adeno-associated virus (AAV) vectors are quickly becoming the vectors of choice for therapeutic gene delivery. To date, hundreds of natural isolates and bioengineered variants have been reported. While factors such...
9.
Kariawasam R, Knight M, Gamsjaeger R, Cubeddu L
Biomol NMR Assign
. 2017 Oct;
12(1):107-111.
PMID: 29063999
Single stranded DNA-binding proteins (SSBs) are essential for the maintenance of genome integrity and are required in in all known cellular organisms. Over the last 10 years, the role of...